Literature DB >> 28244827

Deriving cells expressing markers of female germ cells from premature ovarian failure patient-specific induced pluripotent stem cells.

Yanfei Wen1,2, Wen He1, Manbo Jiang1,3, Minhui Zeng1,4, Liuhong Cai1.   

Abstract

AIM: We proposed a two-step protocol for deriving cells expressing markers of female germ cells (FGCs) from premature ovarian failure patient-specific induced pluripotent stem cells (POF-iPSCs). MATERIAL &
METHODS: We cultured POF-iPSCs in suspension and pretreated them with TGFβ-1 (1 ng/ml) for 2 days and continued with both TGFβ-1 and BMP4 (50 ng/ml) for 5 more days. Then changed to media containing retinoic acid (1 μM) and 5% follicular fluid for another 7 days. Expression of markers of different stages of FGCs were detected.
RESULTS: c-KIT, STELLA/DPPA3, VASA/DDX4, SCP3, GDF9 and ZP3 were positively detected and statistically significant different when compared with control groups.
CONCLUSION: Our in vitro system was beneficial for POF-iPSCs differentiated cells to express STELLA, VASA and SCP3, which were the markers of meiosis initiation of FGCs.

Entities:  

Keywords:  embryoid body; female germ cells; follicular fluid; induced pluripotent stem cells; meiosis; peripheral blood mononuclear cells; premature ovarian failure

Mesh:

Substances:

Year:  2017        PMID: 28244827     DOI: 10.2217/rme-2016-0074

Source DB:  PubMed          Journal:  Regen Med        ISSN: 1746-0751            Impact factor:   3.806


  2 in total

1.  Basal characterization and in vitro differentiation of putative stem cells derived from the adult mouse ovary.

Authors:  Masoumeh Majidi Zolbin; Gulcin Sahin Ersoy; Fereshte Aliakbari; Fardin Amidi; Faezeh Daghigh; Mehdi Abbasi; Joshua Johnson
Journal:  In Vitro Cell Dev Biol Anim       Date:  2020-01-03       Impact factor: 2.416

Review 2.  Stem Cell Therapies for Human Infertility: Advantages and Challenges.

Authors:  Jin-Xiang Wu; Tian Xia; Li-Ping She; Shu Lin; Xiang-Min Luo
Journal:  Cell Transplant       Date:  2022 Jan-Dec       Impact factor: 4.064

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.